We narrowed to 45,626 results for: Ina

#35512-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry (#35512). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123T/T159C)-mCherry plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin E123T/T159C mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Nov. 13, 2025

Academic Institutions and Nonprofits only

#87306-AAV2

Ready-to-use AAV2 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

Aug. 24, 2020

Academic Institutions and Nonprofits only

#35509-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#121675-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

May 31, 2019

Academic Institutions and Nonprofits only

#174378-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-syn-Flpo (#174378). In addition to the viral particles, you will also receive purified pAAV-syn-Flpo plasmid DNA. Syn-driven expression of the recombinase FLPo. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Jin et al Nat Neurosci. 2024 Jan 11. doi: 10.1038/

Oct. 21, 2024

Academic Institutions and Nonprofits only

#87306-AAV1

Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

April 18, 2019

Academic Institutions and Nonprofits only

#131004-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE (#131004). In addition to the viral particles, you will also receive purified pAAV-hSyn-GCaMP 6m-p2A-ChRmine-Kv2.1-WPRE plasmid DNA. hSyn-driven expression of calcium sensor GCaMP6m and bicistronic ChRmine (red-shifted channelrhodopsin). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

June 4, 2020

Academic Institutions and Nonprofits only

#35509-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP (#35509). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin E123T/T159C mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

Feb. 21, 2018

Academic Institutions and Nonprofits only

#87306-AAV9

Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

Jan. 26, 2021

Academic Institutions and Nonprofits only

#87306-AAV5

Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A12.T

Ready-to-use AAV44.9(E531D) in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A01.T

Ready-to-use AAV2 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A09.T

Ready-to-use AAV6 in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A11.T

Ready-to-use AAV44.9 in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A10.T

Ready-to-use AAV6(dbY-F+T-V) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A07.T

Ready-to-use AAV2 (trpYF) in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A06.T

Ready-to-use AAV2 (trpYF) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A04.T

Ready-to-use AAV2 (Y444F) in TMN200 particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A05.T

Ready-to-use AAV2 (Y444F) in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A08.T

Ready-to-use AAV2(4pMut)dHS in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A03.T

Ready-to-use AAV2 in BSS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#157970-AAV.A02.T

Ready-to-use AAV2 in PBS particles produced from pTR-UF11 (#157970). In addition to the viral particles, you will also receive purified pTR-UF11 plasmid DNA. 'Humanized' GFP driven by Chimeric CMV/Chicken Beta Actin promoter

Sergei Zolotukhin

Burger et al Mol Ther. 2004 Aug;10(2):302-17. doi: 10

Dec. 21, 2020

Academic Institutions and Nonprofits only

#87306-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#65014-AAV5

Ready-to-use AAV5 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Feb. 7, 2018

Academic Institutions and Nonprofits only

#105677-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#65014-AAV8

Ready-to-use AAV8 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 13, 2017

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#105669-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CKIIa-stGtACR2-FusionRed (#105669). In addition to the viral particles, you will also receive purified pAAV-CKIIa-stGtACR2-FusionRed plasmid DNA. CaMKIIa-driven, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

July 8, 2020

Academic Institutions and Nonprofits only

#50363-AAV5

Ready-to-use AAV5 particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

May 29, 2019

Academic Institutions and Nonprofits only

#137121-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-GCaMP6M (#137121). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Flp recombinase (inhibited in the presence of Cre recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only